Literature DB >> 8843308

Pharmacokinetics of fluconazole in saliva and plasma after administration of an oral suspension and capsules.

C H Koks1, P L Meenhorst, M J Hillebrand, A Bult, J H Beijnen.   

Abstract

The concentrations of fluconazole were determined at steady state in the saliva and plasma of 10 healthy volunteers after ingestion of fluconazole as capsules and after flushing the mouth for 2 min with the same dose formulated as an oral suspension and swallowing of the drug. Saliva and plasma samples were analyzed by a validated high-performance liquid chromatographic assay. Flushing and swallowing of the oral suspension resulted in a significantly (P = 0.005) higher mean area under the concentration-versus-time curve (AUC) from 0 to 24 h in saliva (89.13 +/- 23.42 mg.h/liter) than that obtained after ingestion of the same dose as capsules (69.27 +/- 12.89 mg . h/liter). The calculated mean maximum concentration in saliva just after swallowing of the suspension was 97.99 +/- 6.12 mg/liter. The peak fluconazole concentration in saliva after the ingestion of the capsules was 3.55 +/- 0.40 mg/liter. The fluconazole oral suspension and capsules resulted in comparable concentrations and AUCs in plasma. Thus, because of a higher local level of drug exposure in terms of both higher peak concentrations in saliva and a higher salivary AUC, the fluconazole oral suspension has theoretical advantages over the capsule formulation in the treatment of oropharyngeal candidiases.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8843308      PMCID: PMC163444     

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  8 in total

1.  MW/Pharm, an integrated software package for drug dosage regimen calculation and therapeutic drug monitoring.

Authors:  J H Proost; D K Meijer
Journal:  Comput Biol Med       Date:  1992-05       Impact factor: 4.589

Review 2.  Resistance of Candida species to fluconazole.

Authors:  J H Rex; M G Rinaldi; M A Pfaller
Journal:  Antimicrob Agents Chemother       Date:  1995-01       Impact factor: 5.191

3.  Salivary concentrations of ketoconazole and fluconazole: implications for drug efficacy in oropharyngeal and esophageal candidiasis.

Authors:  R W Force; M C Nahata
Journal:  Ann Pharmacother       Date:  1995-01       Impact factor: 3.154

Review 4.  Resistance of Candida albicans to azole antifungal agents.

Authors:  C A Hitchcock
Journal:  Biochem Soc Trans       Date:  1993-11       Impact factor: 5.407

5.  Clinically significant mucosal candidiasis resistant to fluconazole treatment in patients with AIDS.

Authors:  S L Newman; T P Flanigan; A Fisher; M G Rinaldi; M Stein; K Vigilante
Journal:  Clin Infect Dis       Date:  1994-10       Impact factor: 9.079

6.  Influence of local radiotherapy on penetration of fluconazole into human saliva.

Authors:  J Oliary; M Tod; K Louchahi; O Petitjean; B Frachet; V Le Gros; N Brion
Journal:  Antimicrob Agents Chemother       Date:  1993-12       Impact factor: 5.191

7.  Fluconazole-resistant candidosis in an HIV cohort.

Authors:  G G Baily; F M Perry; D W Denning; B K Mandal
Journal:  AIDS       Date:  1994-06       Impact factor: 4.177

8.  High-performance liquid chromatographic determination of the antifungal drug fluconazole in plasma and saliva of human immunodeficiency virus-infected patients.

Authors:  C H Koks; H Rosing; P L Meenhorst; A Bult; J H Beijnen
Journal:  J Chromatogr B Biomed Appl       Date:  1995-01-20
  8 in total
  13 in total

1.  Clinical pharmacokinetics of fluconazole in superficial and systemic mycoses.

Authors:  D Debruyne
Journal:  Clin Pharmacokinet       Date:  1997-07       Impact factor: 6.447

2.  In vitro antifungal-drug susceptibilities of mycelial and yeast forms of Penicillium marneffei isolates in Cambodia.

Authors:  Borann Sar; Sambo Boy; Chantary Keo; Chan Chhaya Ngeth; Narom Prak; Mich Vann; Didier Monchy; Jean Louis Sarthou
Journal:  J Clin Microbiol       Date:  2006-09-13       Impact factor: 5.948

3.  Clinical validation of the analysis of fluconazole in oral fluid in hospitalized children.

Authors:  Kim C M van der Elst; Manouche van Alst; Marjolijn N Lub-de Hooge; Kai van Hateren; Jos G W Kosterink; Jan-Willem C Alffenaar; Elisabeth H Schölvinck
Journal:  Antimicrob Agents Chemother       Date:  2014-09-02       Impact factor: 5.191

4.  Effect of Efflux Transporter Inhibition on the Distribution of Fluconazole in the Rat Brain.

Authors:  Wei Wang; Na Zheng; Jiatang Zhang; Xusheng Huang; Shengyuan Yu
Journal:  Neurochem Res       Date:  2017-03-24       Impact factor: 3.996

5.  Correlation of the in vitro antifungal drug susceptibility with the in vivo activity of fluconazole in a murine model of cerebral infection caused by Cryptococcus gattii.

Authors:  F E S Mendes; L V N Oliveira; E S Faria; D G Alvarenga; M R Pinto; C P Taborda; B M Soares; P S Cisalpino; D A Santos
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2010-08-28       Impact factor: 3.267

6.  Investigation of Saliva as an Alternative to Plasma Monitoring of Voriconazole.

Authors:  Kim Vanstraelen; Johan Maertens; Patrick Augustijns; Katrien Lagrou; Henriette de Loor; Raf Mols; Pieter Annaert; Anne Malfroot; Isabel Spriet
Journal:  Clin Pharmacokinet       Date:  2015-11       Impact factor: 6.447

Review 7.  Current and emerging azole antifungal agents.

Authors:  D J Sheehan; C A Hitchcock; C M Sibley
Journal:  Clin Microbiol Rev       Date:  1999-01       Impact factor: 26.132

8.  Design and in vitro/in vivo evaluation of novel mucoadhesive buccal discs of an antifungal drug: relationship between swelling, erosion, and drug release.

Authors:  Soad A Yehia; Omaima N El-Gazayerly; Emad B Basalious
Journal:  AAPS PharmSciTech       Date:  2008-12-11       Impact factor: 3.246

Review 9.  A clinical perspective on mucoadhesive buccal drug delivery systems.

Authors:  Ritu M Gilhotra; Mohd Ikram; Sunny Srivastava; Neeraj Gilhotra
Journal:  J Biomed Res       Date:  2013-06-06

Review 10.  Pharmacokinetics and pharmacodynamics of antifungals in children: clinical implications.

Authors:  Julie Autmizguine; Jeffrey T Guptill; Michael Cohen-Wolkowiez; Daniel K Benjamin; Edmund V Capparelli
Journal:  Drugs       Date:  2014-06       Impact factor: 11.431

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.